UNION CITY, Calif., Sept 20, 2010 /PRNewswire via COMTEX News Network/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) announced today that it will present at the UBS Global Life Sciences Conference on Wednesday, September 22, 2010 at The Grand Hyatt Hotel in New York. Don M. Bailey, President and Chief Executive Officer, will discuss the Company's business strategy and historical financial performance at 3:30 p.m. Eastern Time.
Attendance at this conference is by invitation only. A live audio and slides webcast of Questcor's presentation may be accessed through the Company's website at www.questcor.com. An archived replay of the presentation will be available after the live presentation, and can also be accessed at www.questcor.com.
Questcor Pharmaceuticals is a biopharmaceutical company whose products help patients with serious, difficult-to-treat medical conditions. Questcor's primary product is H.P. Acthar(R) Gel (repository corticotropin injection). H.P. Acthar Gel ("Acthar") is an injectable drug that is approved for the treatment of certain disorders, including the treatment of exacerbations associated with multiple sclerosis ("MS") and to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that is due to lupus erythamatosus. In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms ("IS"), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. For more information, please visit www.questcor.com.
SOURCE Questcor Pharmaceuticals, Inc.
Copyright (C) 2010 PR Newswire. All rights reserved